Evaluation and follow-up of patients with n1-3 m0 or nxm1 prostate cancer in phase iii trials-Reference-Cited by-同舟云学术

Evaluation and follow-up of patients with n1-3 m0 or nxm1 prostate cancer in phase iii trials

Published:1997-04 Issue:4 Volume:49 Page:39-45
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Hall Reginald,Hedlund Per Olov,Ackermann Rolf,Bruchovsky Nicholas,Dalesio Otilia,Debruyne Frans,Murphy Gerald P.,Parmar Mahesh K.B.,Pavone-Macaluso Michele,Ruutu Mirja,Smith Philip

Publisher

Elsevier BV

Subject

Urology

Reference27 articles.

1. Objective Response Criteria in Phase II and Phase III Studies;Jones,1988

2. Proceedings of the International Workshop in Prostatic Cancer and Benign Hypertrophy; Panel V Distant Disease;Newling,1992

3. Prognostic Factor Analysis from EORTC Trials in Advance Prostatic Cancer;de Voogt,1990

4. Survival Analysis, A Practical Approach;Parmar,1995

5. Some statistical considerations for the interpretation of trials of combined androgen therapy;Blumenstein;Cancer,1993

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL;Cancer;2003-11-17

2. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial;BJU International;2002-08-14

3. Prostatic carcinoma with positive lymph nodes – the case for primary hormone therapy;Der Urologe;1999-07

4. Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials.;Journal of Clinical Oncology;1998-10